Wojciech Krzyzanski PhD

Wojciech Krzyzanski

Wojciech Krzyzanski
PhD

Associate Professor

Department of Pharmaceutical Sciences

School of Pharmacy

Contact Information
370 Pharmacy Building
Buffalo, NY 14214-8033
Phone: (716) 645-4847
Fax: (716) 829-6093
wk@buffalo.edu
View map
View faculty website


Overview Research Publications Activities Latest News

Professional Summary:



Education and Training:
  • MA, Pharmacology and Toxicology, SUNY at Buffalo (2006)
  • PhD, Applied Mathematics, SUNY at Buffalo (1997)
  • MA, Mathematics, Jagiellonian University, (1989)

Employment:
  • Associate Professor, Pharmaceutical Sciences, University at Buffalo (2012-present)
  • Assistant Professor, Pharmaceutical Sciences, University at Buffalo (2006–2012)
  • Research Assisatnt Professor, Department of Pharmaceutical Sciences, University at Buffalo (1998–2006)
  • Post Doctoral Fellow, Department of Pharmaceutical Sciences, University at Buffalo (1998)
  • Teaching Assistant, Mathematics, University at Buffalo (1994–1998)
  • Assistant Professor, Institute of Mathematics, Jagiellonian University,, Poland (1989–1994)

Awards and Honors:
  • Kapoor Foundation (2006)
  • Giorgio Segre Prize 2000 in Pharmacokinetics/Pharmacodynamics (2000)

Grants and Sponsored Research:
  • October 2013–October 2015
    Fellowship in Modelling HCV Dynamics
    Janssen Research and Development
    Role: Principal Investigator
    $160,000

Journal Articles:

  • Krzyzanski W, Harrold JM, Wu LS, Perez-Ruixo JJ. A cell-level model of pharmacodynamics-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2016; 43(5).
  • Brenner MC, Krzyzanski W, Chou JZ, Signore PE, Fung CK, Guzman D, Li D, Zhang W, Olsen DR, Nguyen VT, Koo CW, Sternlicht MD, Lipson KE. FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition. Pharm Res. 2016; 33(8).
  • Krzyzanski W, Xiao JJ, Sasu B, Hinkle B, Perez-Ruixo JJ. Pharmacodynamic Model of Hepcidin Regulation of Iron Homeostasis in Cynomolgus Monkeys. AAPS J. 2016; 18(3).
  • Krzyzanski W, Perez-Ruixo JJ, Harrold J. Pharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice. J Pharmacokinet Pharmacodyn. 2015; 42(6).
  • Krzyzanski W. Pharmacodynamic models of age-structured cell populations. J Pharmacokinet Pharmacodyn. 2015; 42(5).
  • Woot de Trixhe X, Krzyzanski W, De Ridder F, Vermeulen A. vRNA structured population model for Hepatitis C Virus dynamics. J Theor Biol. 2015; 378.
  • Singh AP, Krzyzanski W, Martin SW, Weber G, Betts A, Ahmad A, Abraham A, Zutshi A, Lin J, Singh P. Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition. AAPS J. 2015; 17(2).
  • Singh I, Nagiec EE, Thompson JM, Krzyzanski W, Singh P. A systems pharmacology model of erythropoiesis in mice induced by small molecule inhibitor of prolyl hydroxylase enzymes. CPT Pharmacometrics Syst Pharmacol. 2015; 4.
  • Y. Zhang, I. Singh, W. Krzyzanski. Dynamics of erythropoietic markers in response to hypoxia in rats. Journal of Blood Disorders & Transfusion. 2014; 5.
  • M. Elmeliegy, P. Lowe, W. Krzyzanski. Simplification of complex physiologically-based pharmacokinetic models of monoclonal antibodies.. AAPS Journal. 2014; 16.
  • P. Wiczling W. Krzyzanski W, N. Zychlińska, K. Lewandowski, R. Kaliszan. The quantification of reticulocyte maturation and neocytolysis in normal and erythropoietin stimulated rats. Bipharmaceutics & Drug Disposition. 2014; 35.
  • G. Koch, W. Krzyzanski, J. J. Perez-Ruixo, J. Schropp. Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations. Journal of Pharmacokinetics and Pharmacodynamics. 2014; 41.
  • G. Mo, F. Gibbons, P. Schroeder, W. Krzyzanski. Lifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeutics. PLoS ONE. 2014; 9(10).
  • A. P. Singh, W. Krzyzanski, S. W. Martin, G. Weber, A. Betts, A. Ahmad, A. Abraham, A. Zutshi, J. Lin, P. Singh. Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition. AAPS Journal. 2014.
  • Krzyzanski W. Systems pharmacology models for guiding drug design.. CPT: Pharmacometrics & Systems Pharmacology. 2013; 2.
  • W. Krzyzanski, M. E. Brier, T. M. Creed, A. E. Gaweda. Reticulocyte-based estimation of red blood cell lifespan. Experimental Hematology. 2013; 41.
  • Yan X; Ait-Oudhia S; Krzyzanski W. Erythropoietin-induced erythroid precursor pool. Phrmaceutical Research. 2012; 30.
  • Yan X; Chen Y; Krzyzanski W. Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor.. Journal of Pharmacokinetics and Pharmacodynamics. 2012; 39.
  • Yan X; Krzyzanski W. Dose correction for the Michaelis-Menten approximation of the target - mediated drug disposition model.. Journal of pharmacokinetics and pharmacodynamics. 2012; 39.
  • Krzyzanski W; Perez-Ruixo JJ. Lifespan based indirect response models.. 2012.
  • Achuthanandam R; Makropoulos D; Johns L; Volk A; Brosnan K; Lu J; Krzyzanski W; Bugelski PJ. Pharmacodynamics of CNTO 530 and darbepoetin-à in human TNF-? transgenic mice, a murine model of anemia of chronic disease.. Pharmacology and Pharmacy. 2011; 2.
  • Felmlee MA; Krzyzanski W; Morse BL; Morris ME. Use of a Local Sensitivity Analysis to Inform Study Design Based on a Mechanistic Toxicokinetic Model for ?-Hydroxybutyric Acid. AAPS J.. 2011; 13.
  • Krzyzanski W. Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models.. Journal of Pharmacokinetics and Pharmacodynamics. 2011; 38.
  • Ait-Oudhia S; Vermeulen A; Krzyzanski W. Non-linear mixed effects modeling of the time-variant disposition of erythropoietin in anemic cancer patients. Biopharm. Drug Dispos. Biopharmaceutics and Drug Disposition. 2011; 32.
  • Achuthanandam R; Makropoulos D; Johns L; Volk A; Brosnan K; Lu J; Krzyzanski W; Bugelski P. Pharmacodynamics of CNTO 530 and darbepoetin-à in human TNF-? transgenic mice, a murine model of anemia of chronic disease.. Pharmacology and Pharmacy. 2011; 2.
  • Yan X; Mager DE; Krzyzanski W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.. Journal of Pharmacokinetics and Pharmacodynamics. 2010.
  • Wang Y; Krzyzanski W; Doshi S; Xiao JJ; Perez-Ruixo JJ; Chow AT. Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.. AAPS Journal. 2010; 12.
  • Wiczling P; Lowe P; Pigeolet E; Ludicke F; Balser S; Krzyzanski W. Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations. Clinical Pharamcokinetics. 2009; 48.
  • Khinkis LA; Krzyzanski W; Jusko WJ; Greco WR. D-Optimal Designs for Parameter Estimation for Indirect Pharmacodynamic Response Models. J Pharmacokinet Pharmacodyn. 2009; 36.
  • Khinkis LA, Krzyzanski W, Jusko WJ, Greco WR. D-optimal designs for parameter estimation for indirect pharmacodynamic response models. J Pharmacokinet Pharmacodyn. 2009; 36(6).
  • Wiczling P; Aid-Oudhia S; Krzyzanski W. Flow cytometric analysis of reticulocyte maturation after erythropoietin administration in rats. Cytometry Part A. 2009; 75A.
  • Marathe A; Krzyzanski W; Mager DE. Numerical Validation and Properties of a Rapid Binding Approximation of a Target-Mediated Drug Disposition Pharmacokinetic Model. J Pharmacokinet Pharmacodyn. 2009; 36.
  • Krzyzanski W; Perez-Ruixo JJ; Vermeulen A. Basic pharamacodynamic models for agents that alter the lifespan distribution of natural cells. Journal of Pharmacokinetics and Pharmacodynamics. 2008; 35.
  • Wyska E; Krzyzanski W. Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers. Naunyn Schmiedebergs Arch Pharmacol. 2008; 377.
  • Wiczling P; Krzyzanski W. Flow cytometric assessment of homeostatic aging of reticulocytes in rats. Exp Hematol. 2008; 36.
  • PAcrez-Ruixo JJ; Hing J; Krzyzanski W. Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects. Clin Pharmacokinet. 2008; 47.
  • Woo S; Krzyzanski W; Jusko WJ. Pharmacodynamic model for chemotherapy-induced anemia in rats. Cancer Chem. Pharmacol.. 2008; 62.
  • Woo S; Krzyzanski W; Duliege A; Stead RR; Jusko WJ. Population Pharmacokinetics and Pharmacodynamics of Peptidic Erythropoiesis Receptor Agonist (ERA) in Healthy Volunteers. J. Clin. Pharmacol.. 2008; 48.
  • Straubinger RM; Krzyzanski W; Francoforte CM; Qu J. Applications of quantitative pharmacodynamic effect markers in drug target identification and therapy development.. Anticancer Res.. 2007; 27.
  • Woo S; Krzyzanski W; Jusko WJ. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J. Pharmacokin. Pharmacodyn.. 2007; 34.
  • Wiczling P; Krzyzanski W. Method of determination of the reticulocyte age distribution from flow cytometry count by a structured-population model.. Cytometry Part A. 2007; 71A.
  • Krzyzanski W, Oberdoester J, Rabin RA. Mechanism of ethanol enhancement of apoptosis and caspase activation in serum-deprived PC12 cells. Life Sci. 2007; 81(9).
  • Krzyzanski W; Oberdoester J; Rabin RA. Mechanism of ethanol enhancement of apoptosis and caspase activation in serum-deprived PC12 cells. Life Sciences. 2007; 81.
  • Abraham AK, Krzyzanski W, Mager DE. Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition. AAPS J. 2007; 9(2).
  • Krzyzanski W; Bell J. Modelling the geometric features and investigating electrical properties of dendrites in a fish thalamic neuron. Math. Mathematical Medicine and Biology. 2007; 24.
  • Abraham AK; Krzyzanski W; Mager DE. Partial derivative based sensitivity analysis of models describing target-mediated drug disposition. AAPS J. 2007; 9.
  • Krzyzanski W; Perez-Ruixo JJ. An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects.. Pharmaceutical Research. 2007; 24.
  • Krzyzanski W, Dmochowski J, Matsushima N, Jusko WJ. Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models. J Pharmacokinet Pharmacodyn. 2006; 33(5).
  • Woo S; Krzyzanski W; Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats.. Journal of Pharmacology and Experimental Therapeutics. 2006; 319.
  • Krzyzanski W; Dmochowski J; Matsushima N; Jusko WJ. Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models.. Journal of Pharmacokinetics and Pharmacodynamics. 2006; 33.
  • Yao Z; Krzyzanski W; Jusko WJ. Assessment of basic indirect pharmacodynamic response models with physiological limits.. Journal of Pharmacokinetics and Pharmacodynamics. 2006; 33.
  • Krzyzanski W; Woo S; Jusko WJ. Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans.. Journal of Pharmacokinetics and Pharmacodynamics. 2006; 33.
  • Jamal NM; Krzyzanski W; Cheung W; Lau CY; Messner MA. Evaluation of epoetin alpha (rHuEPO) and darbepoetin alpha (DARB) on human burst-colony formation (BFU-E) in culture.. J. Int. Med. Res.. 2006; 34.
  • Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005; 22(10).
  • Wyska E; Mager DE; Krzyzanski W. Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data. J Pharm Sci. 2003; 92.
  • Brenner MC, Krzyzanski W, Chou JZ, Signore PE, Fung CK, D. Guzman, Li D, Zhang W, Olsen DR, Nguyen VTL, Koo CW, Sternlicht MD, Lipson KE. FG-3019, a human monoclonal antibody recognizing connective tissue growth factor, is subject to target-mediated drug disposition.. Pharm Res. ; 33.
See all (46 more)

Professional Memberships:
  • Society for Industrial and Applied Mathematics (2019–present)
  • International Society of Pharmacometrics (2011–present)
  • American Society for Clinical Pharmacology and Therapeutics (2010–2013)
  • American Society of Hematology (2007–2012)
  • American Association of Pharmaceutical Scientists (1998–2017)

Presentations:
  • "Mathematical and Computational Advances in Pharmacometrics" ACoP 7, ISoP, Symposium (2016)
  • "Pharmacodynamic models of age-structured cell populations" ACoP 7, ISoP (2016)
  • "Delay Differential Equations in Pharmacokinetics and Pharmacodynamics" Workshop on Mathematical Pharmacology, Lorentz Center (2015)
  • "Cell-level Model of Pharmacodynamics Mediated Drug Disposition in Chemotherapy Induced Thrombocytopenia" AstraZeneca’s Modelling and Simulation Symposium, AstraZeneca (2014)
  • "Role of Pharmacodynamic Response in Clearance of Drugs Targeting Membrane Bound Proteins" 6th Annual Symposium Center for Protein Therapeutics, University at Buffalo (2014)
  • "A vRNA Structured Population Model of Hepatitis C Virus Dynamics" European Conference on Mathematics and Theoretical Biology, A mini symposium on Modeling Viral Hepatitis Dynamics: From Bench to Bedside (2014)
  • "Lifespan Based Indirect Response Models" PAGANZ 2014, PAGANZ, NONMEM Intermediate Course (2014)
  • "Estimability Of Transit Compartments Model Parameters From Steady State PharmacokineticsData" American Confernce on Pharmacometrics, ISoP (2013)
  • "Lifespan Based Pharmacokinetic-Pharmacodynamic Model of Tumor Growth Inhibition by Anticancer Therapeutics" American Conference on Pharmacometrics, ISoP (2013)
  • "Population Modeling Using Complex Physiologically-Based Models" American Conference on Pharmacometrics, International Society for Pharmacometrics (2013)
  • "Simplification of Complex Physiologically-based Pharmacokinetic Models of Monoclonal Antibodies" American Conference on Pharamcometrics, ISoP (2013)
  • "Simplification of Complex Physiologically-based Pharmacokinetic Models of Monoclonal Antibodies" AAPS National Biotechnology Conference, AAPS (2013)
  • "Bridging the Gap Between Systems Pharmacology and PK/PD to Enhance Drug development The case of erythropoiesis-stimulating agents." PKPD Summit IV (2013)
  • "Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents" ASCPT Annual Meeting 2013, ASCPT (2013)
  • "Quantitative Prediction of Human PK for mAbs exhibiting Target-mediated Disposition:" ASCPT Annual Meeting 2013, ASCPT (2013)
  • "Comparisons between corrected and dose-corrected Michaelis-Menton approximations of Target-mediated drug disposition model" AAPS Annual Meeting 2012, AAPS (2012)
  • "Reticulocyte-Based Estimation of Red Blood Cell Lifespan" American Society of Nephrology Kidney Week, American Society of Nephrology (2012)
  • "Methods of Solving Rapid Binding Target-Mediated Drug Disposition Model for Two Drugs Competing for the Same Receptor" Population Approach Group Europe (2012)
  • "Advancements and Applications of Multiscale Systems Pharmacology Modeling" American Conference on Pharmacometrics, American Society of Pharmacometrics (2011)
  • "Modeling of non-stationary RBC survival: Effect of erythropoietin on RBC mortality vs. production in rats." POPULATION APPROACH GROUP in AUSTRALIA & NEW ZEALAND, University of Auckland (2011)
  • "Treatment of Anemia with Erythropoietin-Stimulating Agents vs. Cardiovasular Toxicities: A Modeling Perspective." BIT's 8th Annual Congress of 2010 International Drug Discovery Science and Technology, BIT Life Sciences (2010)
  • "PK/PD Intrigues of the Erythropoietic System" 12th Buffalo Pharmaceutics Symposium, University at Buffalo (2010)
  • "PK/PD Modeling of the Therapeutic Effects of Erythropoietin" Semiparametric Bayesian Inference Summer Program, Statistical and Applied Mathematical Sciences Institute (2010)
  • "An interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models" Population Approach Group in Europe, Martin-Luther-Universit„t Halle-Wittenberg (2010)
  • "An Age-Structured Population Model of RBC Survival" 6th International Symposium on Measurement & Kinetics of In Vivo Drug Effects, Leiden/Amsterdam Center fof Drug Research (2010)
  • "Minimal Effective Concentration and Efficacy of Epoetins" Bioequivalence and Bioavailability 2010 Pharmaceutical R&D Summit, OMICS Publishing Group (2010)
  • "Comparison of Two Mechanisms for Time Dependent Clearance of Recombinant Human Erythropoietin after Multiple Dosing in Rats" AAPS Annual Meeting (2009)
  • "Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin Following Multiple Dosing in Rats" AAPS Annual Meeting (2009)
  • "Comparison of Pharmacokinetics of Epoetin Alfa Following Multiple Subcutaneous Administrations in Healthy Volunteers and Anemic Cancer Patients" American Conference on Pharmacometrics (2009)
  • "Determinants of Erythropoiesis-Stimulating Agent Efficacy: Exposure vs. Potency" 7th International Drug Discovery Science and Technology Annual Congress (2009)
  • "Modeling and simulations for assessment of pharmacokinetics and pharmacodynamics of a G-CSF biosimilar" American Conference on Pharmacometrics (2009)
  • "Modeling Drug Effects on the Hematopoietic System" The 4th Annual University at Buffalo/ Pfizer meeting, Pfizer Inc (2009)
  • "Pharmacodynamic Model of the Tolerance Effect on Blood Reticulocytes After Multiple Dosing of Recombinant Human Erythropoietin in Rats" AAPS Annual Meeting (2008)
  • "Population Modeling of Filgrastim Pharmacokinetics in Healthy Adults Following Intravenous and Subcutaneous Administrations" AAPS Annual Meeting (2008)
  • "Selection Between Michaelis-Menten and Target-Mediated Drug Disposition Pharmacokinetic Models" AAPS Annual Meeting, AAPS (2008)
  • "Validity of the Rapid Binding Approximation of a Target-Mediated Drug Disposition Model" AAPS Annual Meeting, American Association of Pharmaceutical Scientists (2008)
  • "Effect of Recombinant Human Erythropoietin on Reticulocyte Age Distribution and Survival of RBC" Department of Biochemistry Seminar (2008)
  • "Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin" 2nd World Conference on Magic Bullets (Ehrlich II) (2008)
  • "Effect of Treatment with rHuEPO on RBC Survival in Normal Wistar and Anemic Belgrade Rats" Workshop on Erythropoietin Receptor (EPO-R) Expression and Function in Non-Hematopoietic Tissues, NIDDK (2008)
  • "Effect of Treatment with rHuEPO on RBC Survival in Normal Wistar and Anemic Belgrade Rats" Workshop on Erythropoietin Receptor (EPO-R) Expression and Function in Non-Hematopoietic Tissues., NIDDK (2008)
  • "Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin" European Conference on Mathematical and Theoretical Biology (2008)
  • "Comparison of homeostatic reticulocyte aging between normal and Belgrade rats using flow cytometry" ASH Annual Meeting (2007)
  • "Comparison of Basic Indirect Pharmacodynamic Responses Models and" AAPS Annual Meeting (2007)
  • "Erythropoietin Receptor-Mediated Disposition and Dynamic Model for Human Recombinant Erythropoietin (rHuEPO)" AAPS Annual Meeting (2007)
  • "Flow Cytometric Assessment of Homeostatic Aging of Reticulocytes in Rats" AAPS Annual Meeting (2007)
  • "Mathematical Properties of a Quasi-Equilibrium Model of Target-Mediated Drug Disposition" AAPS Annual Meeting (2007)
  • "Pharmacokinetic and Pharmacodynamic Modeling of AMG 531, a Thrombopoiesis Stimulating Fc Fusion Protein (Peptibody) in Rats and Monkeys" AAPS Annual Meeting (2007)
  • "Pharmacokinetic/Pharmcodynamic Implications of Receptor Dimerazation and Specific Tissue Distribution in Target-Mediated Drug Disposition Models" AAPS Annual Meeting (2007)
  • "Pharmacokinetics and Pharmacodynamics of a Novel Polypeptide Fusion Protein - AMG 623 in Cynomolgus Monkeys" AAPS Annual Meeting (2007)
  • "Pharmacodynamic Modeling of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Age Distribution in Healthy Subjects" PAGE Meeting (2007)
  • "Pharmacokinetics and pharmacodynamics of hematopoietic growth factor receptors" 5th International Symposium on Receptor Mechanisms, Signal Transduction and Drug Effects (2007)
  • "Characterization and application of a new model for the assessment of non-competitive drug-drug interactions" AAPS Annual Meeting (2006)
  • "Development of mathematical model for chemotherapy-induced anemia in rats and its application to selection of rHuEPO dosing strategy" AAPS Annual Meeting (2006)
  • "Local parameter sensitivity analysis of selected target-mediated pharmacokinetic models" AAPS Annual Meeting (2006)
  • "Modeling of effects of recombinant human erythropoietin (rHuEpo) on reticulocyte age distributions in rats" AAPS Annual Meeting (2006)
  • "Population pharmacokinetic and pharmacodynamic modeling of a novel erythropoietin receptor agonist, HematideTM, in healthy volunteers" , AAPS Annual Meeting (2006)
  • "Cell Lifespan Models, Symposium on Modeling Hematopoietic Response" ASCPT Annual Meeting (2005)
See all (47 more)

Service Activities:
  • Internet Assisted Review; National Institutes of Health; Reviewer (2013)
  • Decanal Review Committee; A Decanal Review Committee (DRC) consisting of 2 faculty members (Dr. M. Morris, Chair, and Dr. W. Krzyzanski) and 2 graduate student members (Dr. B. Morse and Mr. M. Kosloski) has been established by Dean Anderson, School of Pharmacy and Pharmaceutical; Member (2012)
  • PharmD Outcomes Assessment Committee; Member (2010–2019)
  • Departmental Awards Committee; Member (2009)
  • Graduate School Grievance Committee; Member (2009)
  • Graduate Admission Committee; Member (2008)
  • HSL Faculty Advisory Committee; Member (2007)
  • SoPPS Admission Committee; Member (2007)
  • Pharmacology Day; Reviewer

School News:

In the Media:

Clinical Specialties:

Clinical Offices:

Insurance Accepted:

Contact Information

370 Pharmacy Building
Buffalo, NY 14214-8033
Phone: (716) 645-4847
Fax: (716) 829-6093
wk@buffalo.edu
View map
View faculty website

Login to Update Your Profile